Designing cost-efficient randomized trials by using flexible recruitment strategies by Menggang Yu et al.
Yu et al. BMC Medical Research Methodology 2012, 12:106
http://www.biomedcentral.com/1471-2288/12/106RESEARCH ARTICLE Open AccessDesigning cost-efficient randomized trials
by using flexible recruitment strategies
Menggang Yu1*, Jingwei Wu2, Debra S Burns3 and Janet S Carpenter4Abstract
Background: Sample size planning for clinical trials is usually based on detecting a target effect size of an
intervention or treatment. Explicit incorporation of costs into such planning is considered in this article in the
situation where effects of an intervention or treatment may depend on (interact with) baseline severity of the
targeted symptom or disease. Because much larger sample sizes are usually required to establish such an
interaction effect, investigators frequently conduct studies to establish a marginal effect of the intervention for
individuals with a certain level of baseline severity.
Methods: We conduct a rigorous investigation on how to determine optimum baseline symptom or disease
severity inclusion criteria so that the most cost-efficient design can be used. By using a regression model with an
interaction term of treatment by symptom severity, power functions were derived for various levels of baseline
symptom severity. Computer algorithms and mathematical optimization were used to determine the most
cost-efficient research designs assuming either single- or dual-stage screening procedures.
Results: In the scenarios we considered, impressive cost savings can be achieved by informed selection of baseline
symptom severity via the inclusion criteria. Further cost-savings can be achieved if a two stage screening procedure
is used and there are some known, relatively inexpensively collected, pre-screening information. The amount of
total cost savings are shown to depend on the ratio of the screening and intervention costs. In our investigation,
we assumed that: 1) the cost of approaching available subjects for screening is constant, and 2) all variables are
normally distributed. There is a need to carry out further investigations with more relaxed assumptions (e.g., skewed
data distribution).
Conclusions: As cost becomes a more and more prominent issue in modern clinical trials, cost-saving strategies
will become more and more important. Strategies, such as the ones we propose here, can help to minimize costs
while maximizing knowledge generation.
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Modern research is costly and faces the ever increasing
pressures of insufficient funding, yet pressing timelines
[1]. Investigators are challenged to maximize the integrity
of their studies in the face of many resource restrictions
such as limited sample sizes, budgetary constraints, less
than ideal follow-up, and short supply of biological sam-
ples. These restrictions are often not under the control of
the investigators. As a result, studies can be under-
powered and end up with inconclusive or inaccurate* Correspondence: meyu@biostat.wisc.edu
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reproduction in any medium, provided the orresults. It is imperative for investigators to explicitly con-
sider and save study costs while optimizing the chance of
generating valid results and conclusions.
In this article, we consider designing randomized clinical
trials where the effect of the targeted treatment or inter-
vention can depend on the baseline symptom or disease se-
verity of enrolled subjects. For example, the treatment may
be more effective for subjects with more severe baseline
symptoms or disease. In statistical terminology, the treat-
ment interacts with the baseline covariate of severity [2-4].
While the ultimate goal is to establish and quantify
such interactions, it can be hard to do so. The main rea-
son is that detecting interaction effects with adequateThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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detecting main effects [3,4], consequently making the study
infeasible or unduly time consuming in the face of resource
restrictions. An alternative and common approach is to
base power analysis on detecting marginal or main treat-
ment effects on subjects that meet pre-determined levels of
symptom severity (e.g., all subjects have severe symptoms).
This ensures that a manageable sample size can be used
to conduct the study in a timely manner. Model based
approaches for interaction are usually specified as a sec-
ondary analysis. For example, instead of conducting a study
to demonstrate the interaction effect of an intervention on
reducing various levels of symptom severity, a smaller
study may be possible due to larger marginal effects of the
intervention in a more severe subpopulation. The estab-
lishment of such an effect is scientifically meaningful but
less useful to clinicians who need to administer treatments
to individuals with varying levels of symptom severity.
On the other hand, it can be more difficult and costly to
recruit subjects due to the stricter eligibility criteria for se-
verity because it implies more screening. If screening costs
are substantial, the total cost of the study may not be
reduced. Also setting too high of a baseline severity require-
ment can increase screening costs because of the added
difficulty of identifying a restricted pool of eligible subjects
(e.g., lower percentage of subjects with severe symptoms).
Thus a trade-off must be made so that resources can be
allocated optimally between screening and treating subjects.
However in most studies, the determination for the cut-off
point for inclusion criteria seems to be based on conveni-
ence or intuition, not on mathematical rigor.
To put the cost consideration concretely, consider a
recent clinical study [5]. The study needs to cover the
salary of recruiter, screenor, intervenor, data collector,
medical record abstractor; it also needs to cover the cost
of enrollment or patient consent, data monitoring and
data entry, drugs or supplies, travel to field - mileage for
follow up and many more. A detailed cost analysis from
[5] reveals that the cost of recruitment for each subject
is 28.7% of the total cost for each subject.
One factor influencing screening costs is whether the
recruitment process is done in one or two stages. In a
two-stage procedure, basic information from potentially
eligible subjects is collected via phone calls or mailings
from the first stage. Subjects are usually asked about
their interest in participation. From the second stage,
only subjects who show interests and appear to be good
candidates are approached for actual onsite screening or
more intensive screening. One-stage procedure either
combines these two stages or omits the first stage effort.
It may be argued that most recruitment processes are
two-stage processes. Separation of the two stages of the
recruitment process allows us to further fine tune the
cost spending in clinical trials to reduce costs.The two-stage procedure has been investigated [6],
where the authors considered only the cost allocation be-
tween the two stages in the recruitment process for finan-
cial savings. Our investigation connects recruitment costs
with intervention costs. We develop methods to balance
these costs to minimize the total costs of clinical trials. In
addition, we illustrate our methods using an example com-
paring costs from various study designs using different
inclusion criteria for baseline symptom severity. We also
verify our numerical calculation using simulation studies.
Methods
Throughout the article, we use intervention and treat-
ment interchangeably to mean the same thing. Consider
a trial comparing control with intervention. Let X be the
baseline symptom severity and Y be the symptom sever-
ity after intervention. Assume the following model for
the effect of intervention:
Y ¼ β0 þ β1 Trt þ β2 X þ β3 Trt  X þ ε: ð1Þ
Here, Trt is the indicator of randomized intervention
which is independent of X and ε ~ N(0, σ2). Therefore both
X and Y are random variables. As usual, we assume that ε is
independent of X. When β3 ≠ 0, we say that there is inter-
vention and covariate interaction. Now suppose we enroll
patients only if their baseline symptom severity exceeds a
threshold a. In the final analysis to declare the marginal ef-
fect of the intervention, we use a two-sample t-test. That is,
we fit a marginal model relating Y to the intervention:
Y ¼ λ0 þ λ1 Trt þ e ð2Þ
The significance of the intervention effect is based on
testing whether λ1 = 0. Although the t-test still takes the
same form algebraically, the statistical distribution needs to
consider the fact that we only enroll subjects with X ≥ a.
From (2), we have λ0 + λ1 Trt = E[Y|Trt, X ≥ a]. From
(1), E[Y|Trt, X ≥ a] = β0 + β1 Trt + β2 E[X|X ≥ a] + β3 E[X|
X ≥ a]Trt, By comparing the coefficients of Trt, we obtain
l1 ¼ β1 þ β3E½XjX≥a Z ð3Þ
This implies when β3 and β1 have the same signs, the
magnitude of λ1 is a monotonic function of a. Hence a lar-
ger effect can be expected from more severe subgroups.
Note that if there is no intervention and baseline symptom
severity interaction, that is, β3 = 0, then λ1 = β1 so the
treatment effect can be estimated in unbiased fashion
from the reduced marginal model (2).
For simplicity, we consider equal size randomization
between the control and intervention groups. Let n be
the sample size for each group and power (n, a) the cor-
responding power for testing H0: λ1 = 0 based on en-
rolled subjects (i.e. those with X ≥ a). Then typically we
require power (n, a) ≥ 90%. For this enrollment sample
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N, which is theoretically equal to n/P(X ≥ a). If we break
the recruitment into two stages where we also collect in-
formation from a pre-screening variable Z on top of X,
we will have corresponding pre-screening size of M and
screening size of N for each group. The relationship
among M, N, and n takes a different form. In the two
stage procedure, the first stage recruits subjects with Z
≥ b to the second stage to obtain X. Those with X ≥ a
are then randomized to either intervention or control.
Then mathematically, we have N = M*P(Z ≥ b), n = N*P
(X ≥ a | Z ≥ b) = M*P(X ≥ a, Z ≥ b).
Designs with a One-stage screening procedure
Recruitment using a one-stage procedure depends on the
screening variable X only. We denote the recruitment,
intervention, and placebo costs by Crec, Ctrt, and Cplacebo
respectively. The total cost is then Crec*2 N + Ctrt *n +
Cplacebo *n. Note that 2 N and 2n are used because we have
two groups (intervention and control) and N and n are
screening and enrolled sizes for each group. Our problem
becomes a mathematical optimization problem: find n and
a such that
Powerðn; aÞ≥90%; n=N ¼ PðX≥aÞ
Ctrt  nþ Cplacebo  nþ Crec  2N is minimize

ð4Þ
We now derive a formula for power (n,a). Let X1 and
X2 be the baseline symptom severities and let Y1 and Y2
be the symptom severities after treatment in the control
and intervention groups respectively.
The t-test for testing H0 :λ1 = 0 can be expressed as
T ¼
Y2  Y1ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ











model (1), the expected value T can be obtained as
EðTÞ ¼ ﬃﬃﬃnp β1 þ β3E½XjX≥aﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
VarðY1jX1≥aÞ þ VarðY2jX2≥aÞ
p
and the variance as Var (T) = 1. Because VarðY1jX1≥aÞ ¼
σ2 þ β22VarðXjX≥aÞ and VarðY2jX2≥aÞ ¼ σ2 þ ðβ2 þ β3Þ2
VarðXjX≥aÞ , the power level based on T for testing H0 :
λ1 ¼ 0 vs. H1: λ1 ≠ 0 can be expressed using t-distribution.
In moderate to large sample sizes, this power can be well
approximated by [7]powerðn; aÞ ¼ Φ ﬃﬃﬃnp β1 þ β3EðXjX≥aÞﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ





B@where Φ( · ) is the cumulative distribution function
(CDF) for a standard normal distribution. To evaluate
power (n,a) for any given n and a, we need to know the
parameter values of β0, β1, β2, β3, σ, and the distribution
of X. The value of σ and the distribution of X can usually
be approximated from historical data or pilot studies. To
specify the values of the regression parameters, noticing
that under the assumption of no control effect, we may
safely assume β0 = 0 and β2 = 1. To solicit values of β1
and β3, we need to obtain the targeted reduction when
using at least two different threshold values of a. This is
natural for investigators to consider due to the inter-
action nature of the intervention. Specifically, we need to
know targeted value λ11 if we set X≥a1 and λ12 if we set
X≥a2: Then from the equations λ11 ¼ β1 þ β3EðX jX
≥a1Þ and λ12 ¼ β1 þ β3EðXjX≥a2Þ; we can obtain tar-
geted values of β1 and β3.
The algorithm for determining the solution to Problem
(4) then proceeds as follows. First, for any given a, we
determine a corresponding n such that the power con-
straint is satisfied. Then, we evaluate the total cost at all
possible range of a and find the optimum value so that
the total cost is minimized.
Designs with a two-stage screening procedure
Quite often, the screening process involves multiple steps
such as 1) identification of potentially eligible subjects via
an existing database; 2) initial screening via phone or mail
using simple measures to exclude those obviously ineli-
gible subjects; and 3) on-site, or phone, or mail screening
using full measures of eligibility criteria.
We consider utilizing the primitive information from
steps 1 and 2, which we call the ‘pre-screening’ stage. In
many cases, the cost associated with pre-screening is rela-
tively inexpensive and information collected at the pre-
screen stage can help offset the higher costs associated
with more intensive screening in step 3. The rationale is
that if we can use the primitive information to predict a
more expensive screening outcome that can depend on
many eligibility criteria, then we should be able to reduce
the number of intensive screenings. As a result, we may
perform more pre-screening in exchange for less intensive
screening. Costs may be saved because of such a trade-off,
especially if pre-screening is inexpensive. In conducting
symptom management studies, the most relevant informa-
tion collected during pre-screening can be self-reported
symptom severity. This is typically rated on a Likert-type
scale (none, mild, moderate, severe) or numeric rating
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pre-screen stage. In other words, Z can be viewed as a sur-
rogate variable for X. The two stage procedure only recruits
subjects with Z≥b for the second stage intensive screening
to obtain X. Those with X≥a are then randomized to either
intervention or control. Assume that we pre-screen M sub-
jects, screen N subjects and enroll n subjects for each
group. Then mathematically, we have N = M*P(Z ≥ b),
n = N*P(X ≥ a | Z ≥ b) = M*P(X ≥ a, Z ≥ b). Denote the
prescreening, screening, intervention, and placebo costs are
denoted by Cpre, Cscr, Ctrt and Cplacebo respectively. The total
cost is Cpre*2 M + Cscr*2 N + Ctrt *n + Cplacebo *n. Hence
our problem becomes a mathematical optimization prob-
lem: find n, a, and b such that
Powerðn; aÞ≥90%; n ¼ N  PðX≥a jZ≥bÞ ¼ M  PðX≥a;Z≥bÞ
Ctrt  nþ Cplacebo  nþ Cscr  2N þ Cpre  2M is minimized

ð6Þ
Note that the total cost can be written as





Because power (n,a) does not involve b, for any given n
and a, we can optimize the total cost as a function of b.
Then the algorithm for the solution to (6) can proceed
similar to the Problem (4). In evaluating the total cost,
we need to know the joint distribution of (X, Z). The
joint distribution may be estimated from existing data
or via a prior specification based on literature search
[8]. In our case, we assume that (X, Z) are jointly normal
variables. The correlation coefficient between X and Z is
denoted by ρ.
Results
In this section, we first illustrate our methods using an
example. We then confirm the accuracy of our numer-
ical calculations in some selected scenarios by compar-
ing our numerical calculations with simulation results.
All our computation is based on the R language version
2.14.1 (http://cran.r-project.org/).
A symptom severity example
Hot flashes are frequent, severe, bothersome events that
interfere with daily life for millions of breast cancer sur-
vivors (BCS) and menopausal women without breast
cancer (MW). Hot flashes have been associated with
mood disturbance, negative affect, and sleep disturbance
in BCS and with sleep disturbance in MW [9,10]. Al-
though hormone therapy is an effective treatment, it is
contraindicated for BCS and no longer acceptable to
many MW because of shifts in its risk-benefit ratio
uncovered by the Women’s Health Initiative study [11].Unfortunately, the scientific basis for non-hormonal
management of hot flashes is limited [12,13].
We are therefore interested in a particular non-
hormonal hot flash treatment that has the potential to re-
duce hot flash symptoms. A randomized clinical trial needs
to be designed to compare the intervention with a control
condition. One of the primary outcomes of the study is hot
flash severity which is measured from 0 (not at all) to 10
(extremely). The effect of this particular intervention is
hypothesized to be greater for those with more severe
baseline hot flashes. However direct testing of such inter-
action term would require a very large sample size. As is
commonly done, we intend to detect marginal treatment
effects on a selected subset of eligible subjects so that a
manageable sample size can be used to conduct the study
in a timely manner. Yet, determination of such a subset is
a common issue in hot flash clinical trials [5,8,13-15].
Although such arbitrariness in determining inclusion criteria
has limited impact on the validity of statistical testing of the
marginal effect, it can affect the cost and timeline of a result-
ing trial, depending on the actual costs of recruitment and
intervention. Intervention usually involves applying the
intervention and following up with enrolled subjects.
Recruitment usually involves costs of accessing databases,
phone interviewing or mailing, on-site screening, etc.
In our example, we have observed that for BCS, about
47% of total costs were spent on recruitment while for
MW, about 17% was spent on recruitment. Because cost
saving percentages are of real interest when comparing
different designs, for simplicity, we take unit intervention
cost Ctrt = $700, unit placebo cost Cplacebo = $700, and
unit recruitment cost Crec = $300. Thus we assume 30% of
total cost is on recruitment. In the two stage screening
procedure, we further break down recruitment cost Crec
into two parts: onsite screening cost Csrc = $200 and pre-
screening cost Cpre = $100.
Using published data, we assume baseline hot flash se-
verity is normally distributed. We take X ~ N(5, 22). We
set the regression coefficients β0 = 0, β1 = -0.2, β2 = 1, and
β3 = -0.25, based on our preliminary analysis of a recently
completed hot flash study. Finally, we take σ = 2.5 as the
standard deviation for the error term. Figure 1 illustrates
our approach and the corresponding results for the one
stage procedure from Section 3.1. The optimum threshold
for our baseline symptom severity inclusion criteria is
found to be a = 5.3, close to the mean (see Figure 1A).
The treatment sample size n (solid line in Figure 1B)
decreases as the threshold increases, whereas the screen-
ing size N (dashed line in Figure 1B) decreases first and
then increases. The rounded optimum screening and
treatment sizes are 193 and 86 respectively. The optimum
cost is $118,100. If the cut-off is taken as 4 (cut off for
moderate severity), the rounded optimum screening and
treatment sizes are 163 and 113 with the corresponding
Figure 1 Plots of total costs (A) and sample size (B) as a function of the symptom severity threshold used for inclusion criteria. The
vertical line indicates the optimum threshold for minimum total cost. The treatment sample size (solid line in B) decreases as the symptom
severity threshold increases, whereas the screening size (dashed line in B) is curvilinear as a function of the symptom severity threshold.
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for severe symptoms), the rounded optimum screening
and treatment sizes are 370 and 60 with the corresponding
total cost of $153,000. Compared with the optimum de-
sign, the cost increases are 8.4% and 29.5% respectively.
To assess how the optimum solutions change as a func-
tion of varying screening costs, we also change the screening
costs while fix the sum of the screening and intervention
costs as $1000. As expected, when the screening cost com-
prises a bigger proportion of the two costs, the optimum
total cost increases (Figure 2A). On the other hand, the
optimum screening sample size decreases (Figure 2B).
Figure 3 plots optimum total costs (Figure 3A) and vari-
ous sample sizes (Figure 3B) as a function of screening
threshold a .The figure compares the two stage and single
stage screening procedures. Here we assume the correl-
ation ρ between Z and X is 0.7. The optimum threshold for
prescreening and screening cut-offs are a = 5 and b = 5.8
under the two stage screening procedure (Figure 3A). This
leads to the rounded-up optimum prescreening, screening
and treatment sizes of 272, 136, and 76 respectively, with a
minimum total cost of $107,600. Compared with the single
stage screening procedure, the cost saving from the two
stage screening procedure is $10,500 (or 8.9%).
As expected, the treatment sample size n (solid line in
Figure 3B) decreases as the threshold increases, whereas
the screening size N and prescreening size M (dashed
line in Figure 3B) decrease first and then increase under
both procedures. Note that the treatment sample size
curve is the same under both procedures as it iscompletely determined from the power function con-
straint, power (n,a) ≥ 90%. We also note that the screen-
ing size curve under the single stage procedure lies in-
between the prescreening and screening sample size
curves under the two stage procedure.
To further investigate how the cost saving change with
the cost of prescreening procedure Cpre, we vary the
ratio while keeping the sum Cpre + Cscr fixed at $300.
Figure 4A plots optimum total costs as a function of
(Cpre + Cscr)
−1Cpre. We see that the smaller the ratio, the
more is the cost saving. This is intuitively clear because
smaller ratios of the prescreening costs translate to more
cost efficient use of the information collected from the
prescreening stage.
To investigate how the cost saving change with the qual-
ity of surrogacy of Z, we vary the correlation coefficient ρ
while keeping the costs as C trt = $700, C placebo = $700,
Cscr = $200, and Cpre = $200. Figure 4B plots optimum
total costs as a function of the correlation coefficient ρ.
We see that the larger the value of the correlation coeffi-
cient, the more the cost savings. This is also intuitively
clear because the higher value of the correlation coeffi-
cient translates to more relevancy in information collected
from the prescreening stage.
Simulation study
In our simulation, we investigate both empirical size and
power of the resulting one stage and two stage screening
procedures. In particular, we generate X ~ N(5, 22) and
Z ~ N(5, 22) with different correlation ρ. The regression
Figure 2 Plots of optimum total costs (A) and optimum screening sample sizes (B) as a function of cost ratios of screening. The
optimum total costs increase as the cost of screening is weighted more heavily in comparison to the cost of intervention (in A), whereas the
screening size decreases (in B).
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are calculated with the regression coefficients β0 = 0, β1 = 0,
β2 = 1, and β3 = 0, whereas the powers are calculated with
β0 = 0, β1 = -0.2, β2 = 1, and β3 = −0.25. These parametersFigure 3 Plots of optimum total costs (A) and sample sizes (B) as a fu
indicate the optimum screening severity threshold for minimum total cost
optimum screening severity threshold for minimum total cost under the si
size under the single stage procedure.were set to mimic the results obtained from a recent study
[5]. The ratio of the prescreening cost over the screening
cost also varies. We also compare the costs from numerical
calculations and from simulated results. The interventionnction of screening severity threshold a. The solid vertical lines
under the two stage procedure. The dashed vertical line indicates the
ngle stage procedure. In B, the gray solid line is the screening sample
Figure 4 Plots of optimum total costs as a function of prescreening cost ratios (A) and of the correlation coefficient ρ (B). The solid
lines correspond to the two stage screening procedure and the dashed line to the single stage procedure.
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the sum of prescreening and screening costs are fixed at
Cscr + Cpre = $300.
Numerical calculations are based on alpha level of 0.05
and power level of 90%. In prescreening, screening, and
treatment sample size determination, we use the least
integers that are larger than calculated sample sizes
(which can be a non-integer number). The prescreening
variable Z, screening variable X, and the actual treat-
ment and outcome are simulated in sequel according to
the determined cut-offs. Simulation results are shown in
Table 1. The actual power levels and test sizes from
simulated data are matching the calculated alpha and
power levels. The actual costs from simulated data are
slightly higher than the calculated costs due to the fact
that we up-round the calculated prescreening, screening,
and treatment sample sizes to integer values. The corre-
sponding marginal treatment values λ1 are also provided.
Conclusions
As cost becomes a more and more prominent issue for
conducting modern clinical trials, cost-saving strategies
should be taken as a priority measure for successful con-
duct of trials. Various aspects of trials should be consid-
ered in the design stage so that the resulting trials are
speedy and economical.
We considered cost-efficient designs for clinical trials
in the case when the effect of an intervention may de-
pend on baseline symptom severity. Optimum baseline
severity threshold for inclusion criteria can be deter-
mined based on an objective cost function so that thestudy can be designed at lower costs. In practice the math-
ematically determined threshold may be rounded to a
practical value near the optimum solution. This round-up
leads to a ‘nearly’ optimum solution and usually has lim-
ited impact on costs. We have presented our results using
90% power. When 80% power is used, similar results in
terms of relative cost savings were observed.
When the recruitment process consists of two stages: a
prescreening stage from either database search or mail/
phone contact of potential subjects and an active (usually
intensive or expensive) screening stage, we demonstrated
that further cost saving can be achieved by utilizing infor-
mation collected from a pre-screening stage if possible.
The interaction parameters are obtained by asking for
targeted improvement or effect of intervention under two
cut-off points for baseline measures. When there are con-
cerns about such solicitation, sensitivity analysis can be
done to clarify the robustness of our results. When there
are different cost-structures associated with the interven-
tion and control groups, our method can be generalized.
Although a t-test without using X is used as the main
analysis due to the pilot nature of early studies and relative
smaller sample size. One should also perform a secondary
analysis using X in the model. Such analysis should be per-
formed once the marginal t-test is significant.
We also note that our formulation can be easily adapted
to different group sizes. Our problem becomes the following
mathematical optimization problem: find n1, n2, and a that
satisfy Power(n1, n2, a) ≥ 90%, such that n1/N1 = P(X ≥ a),
n2/N2 = P(X ≥ a) and Ctrt*n1 + Cplacebo*n2 + Crec*(N1 + N2)
is minimized. Here Power(n1, n2, a) has explicit expression
Table 1 Simulated results for single stage and two stage screening procedures&



























0.10 0.70 $117.5 K $90.8 K $118.3 K $92.0 K 0.91 0.91 0.05 0.05 0.27 0.33
0.20 0.70 $117.5 K $99.9 K $118.4 K $101.5 K 0.90 0.90 0.06 0.05 0.27 0.31
0.30 0.70 $117.5 K $105.6 K $118.3 K $108.3 K 0.89 0.91 0.05 0.05 0.27 0.30
0.40 0.70 $117.5 K $109.5 K $118.3 K $112.0 K 0.89 0.91 0.06 0.06 0.27 0.30
0.50 0.70 $117.5 K $112.4 K $118.4 K $113.4 K 0.90 0.91 0.04 0.05 0.27 0.29
0.33 0.30 $117.5 K $116.8 K $118.5 K $118.9 K 0.90 0.91 0.05 0.05 0.27 0.28
0.33 0.45 $117.5 K $114.5 K $118.5 K $115.8 K 0.89 0.90 0.04 0.05 0.27 0.28
0.33 0.60 $117.5 K $110.5 K $118.5 K $113.3 K 0.89 0.91 0.05 0.05 0.27 0.30
0.33 0.75 $117.5 K $105.2 K $118.3 K $107.6 K 0.90 0.91 0.05 0.06 0.27 0.30
0.33 0.90 $117.5 K $98.0 K $118.5 K $99.8 K 0.90 0.91 0.06 0.04 0.27 0.31
&“Single stage” screening procedure is defined in Section 2.1 where the screening process is viewed as one inseparable part of the clinical trial, this is in contrast
to “two stage” screening procedure where the screening process is broken into a prescreening stage and screening stage (usually intensive or expensive).
†Ratio of prescreening costs to total screening costs. Higher ratio means prescreening costs make up a greater percentage of total screening costs.
‡Correlation coefficient between prescreening and screening variables.
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using t-test with unequal group sizes.
Finally, we list some of limitations in the current investi-
gation. First for simplicity, we only considered normally
distributed outcome and screening variables. There are
certainly other cases of non-normal continuous variables
or discrete variables. Thus, there is a need to carry out a
similar investigation in other situations to make the meth-
odology more generalizable. Second, because the proposed
study design in this article only recruits subjects with X
passing certain threshold, generalizability and interpret-
ation of the conclusion is limited to subjects within same
subset. Third, we also assumed that the cost of approach-
ing available subjects for screening is the same throughout
this article. Such may not be the case. Costs can change
depending on where the subjects are approached. There
can also be a limited number of subjects for screening. In
such cases, the cost of obtaining extra subjects can be pro-
hibitive. These situations can be dealt with using a variant
screening cost function which can depend on the study
sites, number of approached subjects, and/or number of
sites, etc. When such a function can be specified, the
method in this article is directly applicable with slightly
more involved computation.
In summary, we demonstrate a methodology for designing
clinical trials for normally distributed continuous baseline
values of symptom or disease severity. This methodology
can be used to determine the optimum sample size while
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